Volume 21, supplement issue 1, September 2020
Results from the Phase I study programme for navafenterol (AZD8871), a novel inhaled dual pharmacology bronchodilator (MABA)
3 articles in this issue
-
-
Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
Authors (first, second and last of 10)
- Eulalia Jimenez
- Carol Astbury
- Ioannis Psallidas
- Content type: Research
- Open Access
- Published: 09 September 2020
- Article: 211
-
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
Authors (first, second and last of 10)
- Dave Singh
- Victor Balaguer
- Ioannis Psallidas
- Content type: Research
- Open Access
- Published: 09 September 2020
- Article: 102